Tomohiro Nishina
About
Tomohiro Nishina is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Tomohiro Nishina has authored 231 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 154 papers in Pulmonary and Respiratory Medicine and 57 papers in Surgery. Recurrent topics in Tomohiro Nishina's work include Colorectal Cancer Treatments and Studies (131 papers), Gastric Cancer Management and Outcomes (117 papers) and Gastrointestinal Tumor Research and Treatment (36 papers). Tomohiro Nishina is often cited by papers focused on Colorectal Cancer Treatments and Studies (131 papers), Gastric Cancer Management and Outcomes (117 papers) and Gastrointestinal Tumor Research and Treatment (36 papers). Tomohiro Nishina collaborates with scholars based in Japan, United States and Italy. Tomohiro Nishina's co-authors include Narikazu Boku, Kei Muro, Kensei Yamaguchi, Ichinosuke Hyodo, Yoshito Komatsu, Takayuki Yoshino, Atsushi Ohtsu, Taito Esaki, Toshikazu Moriwaki and Shuichi Hironaka and has published in prestigious journals such as Circulation, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Tomohiro Nishina
220 papers receiving 4.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tomohiro Nishina Japan | 35 | 2.7k | 2.2k | 1.1k | 665 | 662 | 231 | 4.3k | ||
| Dong Bok Shin South Korea | 28 | 2.4k 0.9× | 2.5k 1.1× | 1.4k 1.3× | 504 0.8× | 730 1.1× | 112 | 4.2k | ||
| Benjamin Tan United States | 33 | 2.9k 1.1× | 1.9k 0.8× | 1.6k 1.5× | 829 1.2× | 886 1.3× | 163 | 5.0k | ||
| Daisuke Takahari Japan | 29 | 1.8k 0.7× | 1.7k 0.8× | 845 0.8× | 498 0.7× | 524 0.8× | 217 | 3.1k | ||
| Sook Ryun Park South Korea | 31 | 1.9k 0.7× | 3.1k 1.4× | 1.6k 1.5× | 839 1.3× | 1.2k 1.8× | 153 | 4.8k | ||
| David Tougeron France | 36 | 2.4k 0.9× | 1.4k 0.6× | 1.4k 1.3× | 489 0.7× | 384 0.6× | 223 | 3.9k | ||
| Aziz Zaanan France | 33 | 2.2k 0.8× | 1.2k 0.6× | 1.0k 1.0× | 564 0.8× | 641 1.0× | 136 | 3.6k | ||
| Gennaro Galizia Italy | 43 | 2.8k 1.0× | 1.9k 0.8× | 1.3k 1.2× | 1.2k 1.8× | 350 0.5× | 140 | 5.2k | ||
| Christopher R. Garrett United States | 25 | 2.8k 1.0× | 2.4k 1.1× | 953 0.9× | 1.4k 2.1× | 1.1k 1.7× | 50 | 5.3k | ||
| Yoshito Komatsu Japan | 37 | 4.1k 1.5× | 3.5k 1.6× | 2.2k 2.1× | 984 1.5× | 1.1k 1.6× | 319 | 6.6k | ||
| John F. Gibbs United States | 39 | 2.1k 0.8× | 1.6k 0.7× | 1.9k 1.8× | 705 1.1× | 514 0.8× | 150 | 4.7k |
Countries citing papers authored by Tomohiro Nishina
Since
Specialization
Citations
This map shows the geographic impact of Tomohiro Nishina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiro Nishina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiro Nishina more than expected).
Fields of papers citing papers by Tomohiro Nishina
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tomohiro Nishina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiro Nishina. The network helps show where Tomohiro Nishina may publish in the future.
Co-authorship network of co-authors of Tomohiro Nishina
This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiro Nishina. A scholar is included among the top collaborators of Tomohiro Nishina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiro Nishina. Tomohiro Nishina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Machida, Nozomu, Takehiro Okumura, Narikazu Boku, et al.. (2025). A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. 131(7). e35807–e35807.
2.
Siena, Salvatore, Kanwal Raghav, Toshiki Masuishi, et al.. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. 15(1). 10213–10213.
3.
Nishina, Tomohiro, Narikazu Boku, Yukinori Kurokawa, et al.. (2024). A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group. Japanese Journal of Clinical Oncology. 54(10). 1100–1106.
4.
Kotani, Daisuke, Hideaki Bando, Hiroya Taniguchi, et al.. (2024). Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).. Journal of Clinical Oncology. 42(16_suppl). 3585–3585.
5.
Furuse, Junji, Masafumi Ikeda, Makoto Ueno, et al.. (2024). A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clinical Cancer Research. 30(18). 3990–3995.
6.
Kajiwara, Takeshi, Tomohiro Nishina, Yoshiaki Nakamura, et al.. (2023). Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers. 15(21). 5172–5172.
7.
Nishina, Tomohiro, et al.. (2022). Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study. BMJ Open. 12(10). e055718–e055718.
8.
Siena, Salvatore, Kanwal Raghav, Toshiki Masuishi, et al.. (2021). 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Annals of Oncology. 32. S532–S532.
9.
Kawazoe, Akihito, Yasutoshi Kuboki, Eiji Shinozaki, et al.. (2020). Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research. 26(22). 5887–5894.
10.
Nakajima, Takako Eguchi, Shigenori Kadowaki, Keiko Minashi, et al.. (2020). Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research. 27(4). 1029–1036.
11.
Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2020). SO-25 A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701). Annals of Oncology. 31. S226–S226.
12.
Morizane, Chigusa, Makoto Ueno, Masahiro Tajika, et al.. (2020). 128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090. Annals of Oncology. 31. S1292–S1293.
13.
Shitara, Kohei, Yoshitaka Honma, Yasushi Omuro, et al.. (2019). Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2‐positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia-Pacific Journal of Clinical Oncology. 16(1). 5–13.
14.
Shitara, Kohei, Hiroki Hara, Takaki Yoshikawa, et al.. (2019). Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. International Journal of Clinical Oncology. 25(2). 301–311.
15.
Yamada, Yasuhide, Wasaburo Koizumi, Kazuhiro Nishikawa, et al.. (2019). Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer. Cancer Science. 110(9). 2875–2883.
16.
Masuishi, Toshiki, Hiroya Taniguchi, Daisuke Kotani, et al.. (2019). Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open. 4(6). e000590–e000590.
17.
Nagasaka, Takeshi, Hideyuki Mishima, Akira Sawaki, et al.. (2016). Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C 3 ) study. BMJ Open. 6(6). e011454–e011454.
18.
Yamaguchi, Kensei, Akira Sawaki, Toshihiko Doi, et al.. (2012). Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 16(2). 175–182.
19.
Hirasaki, Shoji, Ichinosuke Hyodo, Takeshi Kajiwara, Tomohiro Nishina, & Toshikazu Masumoto. (2004). [Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography].. PubMed. 101(1). 41–6.
20.
Yamamoto, Masato, Katsuji Nishimura, Tomohiro Nishina, et al.. (2000). Prevasculrization using gelatin microsphere containing basic-fibroblast growth factor enhances the benefits of cardiomyocytes transplantation in rats with ischemic cardiomyopathy.. Circulation. 102(18). 650–650.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dong Bok Shin Breakdown of academic impact, for papers by Benjamin Tan Breakdown of academic impact, for papers by Daisuke Takahari Breakdown of academic impact, for papers by Sook Ryun Park Breakdown of academic impact, for papers by David Tougeron Breakdown of academic impact, for papers by Aziz Zaanan Breakdown of academic impact, for papers by Gennaro Galizia Breakdown of academic impact, for papers by Christopher R. Garrett Breakdown of academic impact, for papers by Yoshito Komatsu Breakdown of academic impact, for papers by John F. Gibbs